Plain-English translation of NCT05730283 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication called can protect your hearing when you receive amikacin, an antibiotic given by IV for a chronic lung infection. Amikacin can sometimes damage the inner ear and cause hearing loss, but this study is investigating whether taking this medication alongside your antibiotic might prevent that damage. You would take either the new medication, a lower dose of it, or a placebo (inactive pill) while you're receiving your antibiotic treatment.
Amikacin is an important antibiotic for treating serious lung infections, but it can damage hearing in some patients. Researchers want to find out if this new treatment can protect your ears from that damage, allowing patients to safely receive the antibiotic they need without losing their hearing.
You likely qualify if…
You likely don't qualify if…
You would take a daily capsule (either the new medication at a high or low dose, or placebo) starting when you begin your IV amikacin treatment. You would continue taking this daily capsule for up to 90 days or until your amikacin treatment ends, whichever comes first. During the study, you would have hearing tests and check-ins to see how your ears are responding, and the researchers would monitor your safety throughout your participation.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States